Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA

Author: Benzinga Newsdesk | April 25, 2024 02:57am

• QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy
• Positive results seen in both PD-L1 negative and PD-L1 positive participants with NSCLC
• Data reaffirms the mechanism of action of ANKTIVA as an immune cell enhancer that activates natural killer (NK) cells and memory T cells to rescue checkpoint inhibitor (pembrolizumab, nivolumab, atezolizumab) failures across multiple tumor types
• Meeting scheduled with FDA in June to discuss path to registration filing of ANKTIVA plus checkpoint inhibitors in 2nd- and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy
• $100 million in non-dilutive cash infusion with ANKTIVA approval brings cash-on-hand to approximately $240 million for launch of ANKTIVA in non-muscle invasive bladder cancer (NMIBC)
• Company has scheduled a conference call to discuss registration plans for NSCLC, status of ANKTIVA launch readiness for NMIBC, and ANKTIVA as the backbone of our clinical trial pipeline for multiple tumor types

Posted In: IBRX